Protease inhibitor fosamprenavir potent against advanced HIV disease

"Fosamprenavir, the prodrug formulation of amprenavir, is a protease inhibitor recently approved in the US for the treatment of HIV infection. This agent combines the pharmacological profile of amprenavir with a low pill burden and flexible dosing schedule. Three large international trials have been completed," investigators in the United States report.

"In treatment-naive patients," wrote S. Becker and colleagues, "fosamprenavir, both ritonavir-boosted and -unboosted, met primary end points of non-inferiority against nelfinavir. Among naive patients, no protease inhibitor...

Want to see the full article?

• Purchase this article for only $3.00